Erratum - Erratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms

Sep 29, 2026

Erratum addresses an error in Figure 8A of the original article “Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms” (doi: 10.21037/atm-22-1459). The images showing tumorigenesis of AML xenograft mice treated with venetoclax and HHT alone or in combination were misused. Corrected Figure 8A is provided with the right panels and the proper version of Figure 8. Authors confirm the mistake does not significantly affect results or conclusions.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages4

Reading Time10 min

AccessFree to download

Erratum notice

Error description in Figure 8A

Corrected Figure 8 and confirmed impact

Publication and licensing information

Reference and citation

Erratum Erratum to Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms Editorial Office Annals of Translational Medicine [Correspondence to:](Correspondence to: Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org)[ Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org](Correspondence to: Editorial Office. Annals of Translational Medicine. Email: editor@atmjournal.org). Submitted Sep 13, 2024. Accepted for publication Sep 19, 2024. Published online Nov 13, 2024. doi: 10.21037/atm-2024-32 View this article at: [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32) Erratum to: Ann Transl Med 2022;10:490 . The article (1) titled “Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms”(doi: 10.21037/atm-22-1459) unfortunately contains an error in Figure 8. In Figure 8A, the images representing the tumorigenesis of AML xenograft mice treated with venetoclax and HHT alone or in combination were misused. Figure 8A of the original article: Day 0 Day 4 Day 7 Day 10 Control Venetoclax HHT Combination 5.0 4.0 3.0 ×105 2.0 1.0 5.0 4.0 3.0 ×106 2.0 1.0 5.0 4.0 3.0 ×107 2.0 1.0 5.0 4.0 3.0 ×108 2.0 1.0 © AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32) Page 2 of 4 Editorial Office. Erratum Figure 8A after correction: Control Venetoclax HHT Combination Day 0 Day 4 Day 7 Day 10 5.0 4.0 3.0 ×105 2.0 1.0 5.0 4.0 3.0 ×106 2.0 1.0 5.0 4.0 3.0 ×107 2.0 1.0 5.0 4.0 3.0 ×108 2.0 1.0 © AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32) Annals of Translational Medicine, Vol 13, No 6 December 2025 Page 3 of 4 The correct version of Figure 8 was shown below: A Day 0 Day 4 Day 7 Day 10 Control Venetoclax HHT Combination 5.0 4.0 3.0 ×105 2.0 1.0 5.0 4.0 3.0 ×106 2.0 1.0 5.0 4.0 3.0 ×107 2.0 1.0 5.0 4.0 3.0 ×108 2.0 1.0 B Bioluminescence intensity C D Lung Liver Spleen Lung Liver Spleen Control Venetoclax HHT Combination E F Count 150 100 50 0 100 Control Venetoclax HHT Combination CD45 PerCP subset CD45 PerCP subset CD45 PerCP subset CD45 PerCP subset 34.4 24.2 3.05 0.30 101 102 103 104 100 101 102 103 104 100 101 102 103 104100 101 102 103 104 50 40 30 20 10 0 Control Venetoclax HHT Combination ** ** ** hCD45+,% G 24 22 20 18 16 Weight, g Control Venetoclax ** HHT Combination 0 5 10 H ** ** Survival,% 100 50 0 Control Venetoclax * HHT Combination * ** 0 10 20 30 Days Days © AME Publishing Company. Ann Transl Med 2025;13(6):85 | [https://dx.doi.org/10.21037/atm-2024-32](https://dx.doi.org/10.21037/atm-2024-32) Page 4 of 4 Editorial Office. Erratum The authors confirmed this error did not significantly affect either the results or the conclusions of the paper. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons AttributionNonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: [https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by-nc-nd/4.0/](licenses/by-nc-nd/4.0/.)[.](licenses/by-nc-nd/4.0/.) References 1. Yuan F, Li D, Li G, et al. Synergistic efficacy of homoha

FAQs

What error is corrected in this erratum?

The erratum corrects an error in Figure 8A of the original article, where images representing tumorigenesis of AML xenograft mice were misused.

Which treatment groups are shown in the corrected Figure 8A?

Figure 8A includes groups treated with control, venetoclax, HHT, and the combination, across multiple time points (Day 0, Day 4, Day 7, Day 10).

Does the corrected figure change the study’s overall conclusions?

The authors confirmed the error does not significantly affect either the results or the conclusions of the paper.

Sep 29, 2026

Uploaded by Quinn Holloway